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1388-2457/ 2017 International Federation of Clinical Neurophysiology.We thank Burke and Kiernan for their interesting and construc-
tive comments (Burke and Kiernan, 2018) on our recent Letter to
the Editor (Milants et al., 2017). We agree with most of these com-
ments. It is absolutely correct that by considering only iMAX, we
lose valuable information related to the stimulus-response curve,
particularly the curve slope or discontinuities in the curve as it
can be seen in amyotrophic lateral sclerosis. Nevertheless, the
delta between iMAX and motor threshold values might contain a
similar information to the curve slope. Moreover, we wanted an
as fast and simple procedure as possible without data importation
and analysis in a spreadsheet data.
The Cappelen-Smith et al.’s paper (Cappelen-Smith et al., 2001)
is of major importance in the field of excitability and was crucial in
our choice to develop iMAX. In their Fig. 1, mentioned by Burke
and Kiernan (2018), the relationship between compound muscle
action potential (CMAP) amplitude (% maximum) and current (A)
or normalized current (B), the greatest differences between
healthy controls and patients with chronic inflammatory demyeli-
nating polyneuropathy were for the highest CMAP amplitudes
(CMAP 90% of maximum amplitude). Therefore, we postulated that
it would be of interest to measure the amount of current for a
CMAP 100% of maximum amplitude. iMAX was easily derived in
healthy controls for the median nerve at the wrist and we are con-
vinced that the 7.0 mA value is a reliable upper limit of normal. As
indicated by Burke and Kiernan (2017), it may be trickier to pre-
cisely measure iMAX in patients with a severe motor axonal
hypoexcitability. However, in the daily practice, if iMAX is clearly
increased, even if the precise iMAX value is tricky to obtain, the
clinician gets, in a couple of minutes, the valuable information that
there is a significant motor axonal hypoexcitability, which is of
major importance from a clinical point of view. Burke and
Kiernan (2018) suggest that the current for a 40–50% CMAP might
prove to be more reliable than iMAX. On one hand, prior to mea-
sure the current for a 40–50% CMAP, a CMAP 100% of maximum
amplitude has to be evoked as precisely as possible, which in some
way brings us back to iMAX. On the other hand, we wanted mea-
suring the motor axons with the highest threshold of all axons
including aberrant axons of a very high threshold.
The stimulus-response curve methodology and the computer-
ized threshold tracking procedure (Bostock et al., 1998; Kiernan
et al., 2000; Burke et al., 2001; Cappelen-Smith et al., 2001) are
not without limitations. As already said, these methods are time
consuming and they require a specific collection system and soft-
ware (Milants et al., 2017). Moreover, in a multicenter study using
a stimulus-response procedure, the variability of results was high,
for most of the parameters, not only between the centers, but also
within the centers as indicated by the test-retest evaluation (forPublished by Einstance, coefficients of variation for slope estimates and for normal-
ized slope estimates, respectively, ranged from19.28% to34.73%and
from15.12% to 27.91%) (Boërio et al., 2007). In a very recent abstract,
Bostock himself wrote ‘‘However, nerve excitability testing remains
a specialized technique: it is not possible on regular EMGmachines,
it is not required for any common diagnostic test, and abnormal
recordings are often difficult to interpret.” (Bostock, 2017)
To answer the question asked by Burke and Kiernan (2018)more
directly,what is really newwith iMAX?: (1) look at a particular, usu-
ally neglected, point of the stimulus-response curve (the amount of
current for a CMAP 100% of maximum amplitude); (2) develop an
up-down-up stimulus intensity procedure tomeasure themore pre-
cisely as possible iMAX; and (3) allow everyone, in the daily practice
and whatever the EMG machine, to answer the question very
quickly if there is, or not, a motor axonal hypoexcitability.
At last, the present study is preliminary. We wish to measure
iMAX to other points of the peripheral nervous system, as at the
elbow (median and ulnar nerves) and at the fossa polplitea (fibular
nerve), in healthy controls and in large cohorts of patients with
hereditary or acquired axonal and demyelinating neuropathies. A
multicenter study will be soon started in order to evaluate, at least
in healthy controls, the variability of iMAX within and between
centers.
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